1.
The mutational status of platelet-receptor PEAR1 was recently identified as a major factor for survival of young patients with Acute Myeloid Leukemia. While studies show [...]
2024 | Abstract |
2.
Identification of druggable mutations in Acute Myeloid Leukemia (AML), such as FLT3-ITD, has led to the development of targeted therapies capable of out-performing cytoto [...]
2022 | Abstract |